论文部分内容阅读
当前酒精性肝病(ALD)患病率居高不下,而非酒精性脂肪性肝病(NAFLD)发病率不断攀高,且起病渐趋低龄化,两者与病毒性肝炎并存者亦不少见。更为可怕的是,NAFLD不但与ALD相似,可导致肝硬化、肝细胞癌和肝功能衰竭,而且与2型糖尿病以及动脉硬化性心脑血管事件关系密切。然而迄今尚缺乏防治脂肪性肝病(FLD)的特效药物,现有对策主要为“提高认识、综合防治,加强宣教,重在实施”。
The current prevalence of alcoholic liver disease (ALD) is high, while the incidence of nonalcoholic fatty liver disease (NAFLD) is on the rise, and the incidence is getting younger and younger. Both are associated with viral hepatitis. Even more frightening is NAFLD is not only similar to ALD, can lead to cirrhosis, hepatocellular carcinoma and liver failure, but also with type 2 diabetes and atherosclerotic cardiovascular events. However, so far there is no specific drug for the prevention and treatment of fatty liver disease (FLD). The existing countermeasures are mainly to “raise awareness, comprehensive prevention and control, strengthen education, and focus on implementation.”